Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:01 2024-04-24 pm EDT			5-day change	1st Jan Change
40.93 ^USD	-0.22%		+3.57%	+5.87%

Apr. 23	Edwards Lifesciences Corporation: The story continues
Apr. 15	Exact Sciences Names Aaron Bloomer CFO	MT

Baxter International : Dedicated to Our Patients' Needs

September 24, 2021 at 09:12 am EDT

Patients

Critical Care
Hospital Care
Nutritional Care
Renal Care
Surgical Care

Healthcare Professionals

Critical Care
Hospital Care
Nutritional Care
Renal Care
Surgical Care
Our Products
Safety Data Sheets
Authorized Distributors

Perspectives

Patients' Stories
Healthcare Insights
People of Baxter
Community Engagement

Our Story

Our Leadership
Our Governance
Fueling Collaborative Innovation
Corporate Responsibility
Inclusion & Diversity
Our History
Policies & Positions
Product Security

COVID-19
News
Investors
Careers
Partners and Suppliers
Contact Us
Global Site

Global Privacy Policy
California Privacy
HIPAA Notice of Privacy Practices
Terms of Use
Cookies
Site Map

Attachments

Original document
Permalink

Disclaimer

Baxter International Inc. published this content on 24 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2021 13:11:06 UTC.

Latest news about Baxter International Inc.

Edwards Lifesciences Corporation: The story continues	Apr. 23
Exact Sciences Names Aaron Bloomer CFO	Apr. 15	MT
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S	Apr. 11	CI
Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period	Apr. 04	MT
Citigroup Raises Price Target on Baxter International to $44 From $41, Keeps Neutral Rating	Apr. 03	MT
Baxter International Receives US FDA Clearance for Novum IQ Large Volume Infusion Pump	Apr. 01	MT
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy	Apr. 01	CI
Baxter International Files Definitive Proxy Statement with Securities and Exchange Commission	Mar. 25	CI
Baxter International Inc. Enters into Fourth Amendment to the Existing $4.0 Billion Term Loan Credit Facility	Mar. 21	CI
Baxter International Receives a Shareholder Proposal from John Chevedden	Mar. 14	CI
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data	Mar. 05	RE
Baxter International Now Considering Sale of Kidney Care Business to Private Equity Investors	Mar. 05	MT
Dialysis firms gain as Ozempic kidney trial data disappoints	Mar. 05	RE
Transcript : Baxter International Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 04:00 PM	Mar. 04
Baxter International Provides an Update on the Planned Separation of its Kidney Care Business	Mar. 03	CI
Transcript : Baxter International Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 11:00 AM	Feb. 29
Spectral Medical Says PMX Distribution and Supply Agreement with Baxter International Extended for 10 Years	Feb. 21	MT
Spectral Medical Announcing "Major Milestone" by Reaching Its Interim Enrollment Target of 90 Patients	Feb. 15	MT
Baxter International Maintains Quarterly Dividend at $0.29 a Share, Payable April 1 to Shareholders of Record March 1	Feb. 13	MT
Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024	Feb. 12	CI
UBS Adjusts Baxter International Price Target to $42 From $40, Maintains Neutral Rating	Feb. 09	MT
Deutsche Bank Adjusts Baxter International Price Target to $42 From $35, Maintains Hold Rating	Feb. 09	MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1, 2024 Earnings Forecasts	Feb. 08	MT
Correction: Baxter International's Q4 Adjusted Earnings, Revenue Rise; Issues Q1 and 2024 Earnings Outlook; Shares Drop	Feb. 08	MT
Sector Update: Health Care Stocks Steady Premarket Thursday	Feb. 08	MT

Chart Baxter International Inc.

Duration

Period

More charts

Company Profile

Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Baxter International Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.93 USD

Average target price

47.4 USD

Spread / Average Target

+15.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BAXTER INTERNATIONAL INC.	+5.87%	20.85B
ABBOTT LABORATORIES	-2.89%	185B
MEDTRONIC PLC	-2.43%	107B
BECTON, DICKINSON AND COMPANY	-4.10%	67.55B
DEXCOM, INC.	+11.10%	54.6B
CENCORA, INC.	+15.86%	47.42B
HOYA CORPORATION	+3.86%	42.24B
WEST PHARMACEUTICAL SERVICES, INC.	+9.55%	28.24B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.85%	26.42B
TERUMO CORPORATION	+12.40%	25.66B

Other Medical Equipment, Supplies & Distribution